ArticleThe Indian journal of medical research2016
Subinhibitory concentration of ciprofloxacin targets quorum sensing system of Pseudomonas aeruginosa causing inhibition of biofilm formation & reduction of virulence.
Article in The Indian journal of medical research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 67 citations in OpenAlex.
- Beyond lethal doses: sub-MIC levels of multi-class antibiotics induce species- and isolate-dependent biofilm inhibition in gram-negative pathogens.BMC microbiology · 2026Article
- Transient sub-MIC ciprofloxacin exposure produces a stress-conditioned Pseudomonas aeruginosa phenotype that enhances NF-κB activation and inflammatory injury in lung epithelial cells.Archives of microbiology · 2026Article
- Chlorpromazine, impregnated in foley catheter fragments, as an antibiofilm agent to control urinary tract infections.Future microbiology · 2025Article
- Growth-Phase-Dependent Modulation of Quorum Sensing and Virulence Factors inAntibiotics (Basel, Switzerland) · 2025Article
- Comparison of the antibiofilm activity of plant-derived compounds furanone C30 and ellagic acid C11 with antibiotics against Pseudomonas aeruginosa.Northern clinics of Istanbul · 2025Article
- Ocular surface microbiota alterations in patients with pterygium.Frontiers in cellular and infection microbiology · 2025Article
- Potential antivirulence activity of sub-inhibitory concentrations of ciprofloxacin against Proteus mirabilis isolates: an in-vitro and in-vivo study.Annals of clinical microbiology and antimicrobials · 2024Article
- Evaluation of the in vitro effects of concentrations of antibiotics on three Enterobacteriaceae isolates.World journal of microbiology & biotechnology · 2024Article
- Synergistic Effect of Thymol-Ciprofloxacin Combination on Planktonic Cells and Biofilm of Pseudomonas aeruginosa.Current microbiology · 2023Article
- Biosynthesized Silver Nanoparticles Derived from ProbioticAntibiotics (Basel, Switzerland) · 2023Article
- A Library of Promoter-Applied and environmental microbiology · 2023Article
- Need for standardization in sub-lethal antibiotics research.Frontiers in microbiology · 2023Review
- Ciprofloxacin enhances the biofilm formation ofFrontiers in microbiology · 2023Article
- Synergistic Effects of Gentamicin, Cefepime, and Ciprofloxacin on Biofilm ofInfection and drug resistance · 2023Article
- Low Ciprofloxacin Concentrations Select Multidrug-Resistant Mutants Overproducing Efflux Pumps in Clinical Isolates of Pseudomonas aeruginosa.Microbiology spectrum · 2022Article
- Repurposing phytochemicals as anti-virulent agents to attenuate quorum sensing-regulated virulence factors and biofilm formation in Pseudomonas aeruginosa.Microbial biotechnology · 2022Review
- Different effects of sub-minimum inhibitory concentrations of gentamicin on the expression of genes involved in alginate production and biofilm formation ofIranian journal of microbiology · 2021Article
- Sub-Inhibitory Antibiotic Exposure and Virulence inAntibiotics (Basel, Switzerland) · 2021Review
- Maximum levels of cross-contamination for 24 antimicrobial active substances in non-target feed. Part 10:EFSA journal. European Food Safety Authority · 2021Article
- The Impact of an Efflux Pump Inhibitor on the Activity of Free and Liposomal Antibiotics againstPharmaceutics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
objectivesBiofilms formed by pseudomonas aeruginosa lead to persistent infections. Use of antibiotics for the treatment of biofilm induced infection poses a threat towards development of resistance. Therefore, the research is directed towards exploring the property of antibiotics which may alter the virulence of an organism besides altering its growth. The aim of this study was to evaluate the role of subinhibitory concentration of ciprofloxacin (CIP) in inhibiting biofilm formation and virulence of P. aeruginosa.
methodsAntibiofilm potential of subinhibitory concentration of CIP was evaluated in terms of log reduction, biofilm forming capacity and coverslip assay. P. aeruginosa isolates (grown in the presence and absence of sub-MIC of CIP) were also evaluated for inhibition in motility, virulence factor production and quorum sensing (QS) signal production.
resultsSub-minimum inhibitory concentration (sub-MIC) of CIP significantly reduced the motility of P. aeruginosa stand and strain and clinical isolates and affected biofilm forming capacity. Production of protease, elastase, siderophore, alginate, and rhamnolipid was also significantly reduced by CIP. INTERPRETATION &
conclusionsReduction in virulence factors and biofilm formation was due to inhibition of QS mechanism which was indicated by reduced production of QS signal molecules by P. aeruginosa in presence of subinhibitory concentration of CIP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.